Travere Therapeutics, Inc. - Common Stock (TVTX)

Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open.  UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s. Previous close: $26.99. An 81% gain, overnight.  Read that last number again. This stock nearly doubled in a single session.  Now, I…

This rare disease therapeutics specialist reported a notable insider sale amid a year of strong share price gains and pipeline progress.

Travere Therapeutics (NASDAQ:TVTX) reported a profit in Q1, surpassing analyst estimates. Shares fell 1.1% on Tuesday, analysts have raised price targets.

Travere (TVTX) Q1 2026 Earnings Transcript

Travere (TVTX) Q2 2025 Earnings Transcript

Travere (TVTX) Q4 2025 Earnings Transcript

Focused on rare disease therapies, this biotech firm reported a notable insider sale amid a year of substantial share price gains.

Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.

Let's have a look at the gap up and gap down stocks in today's session.

Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.

In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (NASDAQ: BIIB) announced today, March 31, 2026, that it has entered into a definitive agreement to acquire Apellis Pharmaceuticals (NASDAQ: APLS) for approximately $5.6 billion in cash. The deal, valued at $41 per

Shares of Vertex Pharmaceuticals (Nasdaq: VRTX) climbed more than 8% today, reaching a record high as the biotechnology giant unveiled spectacular interim results from its pivotal Phase 3 RAINIER trial. The data, which focused on povetacicept for the treatment of IgA nephropathy (IgAN), showcased a 52% reduction in proteinuria, a

Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.

This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.

Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

A regulatory decision on a top investigational drug won't be coming as soon as hoped.

On January 13, 2026, Travere Therapeutics (NASDAQ: TVTX) faced a sharp reversal of fortune as the U.S. Food and Drug Administration (FDA) announced a three-month extension for its review of Filspari (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The news sent shockwaves through the biotech sector, causing